


WORKING THROUGH LATENT TUBERCULOSIS INFECTION (LTBI)
 HIV-NEGATIVE ADULTS
 A DIAGNOSIS AND MANAGEMENT ALGORITHM FOR PRIMARY CARE PROVIDERS


Washtenaw County Health Department Tuberculosis (TB) Control Program
 March 21, 2019



1

OBJECTIVES

- Understand the importance of LTBI screening and treatment in the role of TB elimination.
- Review Washtenaw County's LTBI testing, diagnosis, and treatment algorithm.
- Discuss how Washtenaw County uses this algorithm to address LTBI in the county.



2

**WASHTENAW COUNTY HEALTH DEPARTMENT
 TUBERCULOSIS (TB) CONTROL PROGRAM**


SERVICES	STAFF
<ul style="list-style-type: none"> • Bi-monthly evening clinic • 24 hour support <ul style="list-style-type: none"> • Patients • Local and regional health care providers • Direct Observational Therapy (DOT) <ul style="list-style-type: none"> • Traditional (in-person) DOT • Video DOT • Case-management 	<ul style="list-style-type: none"> • TB Physician Consultant: <ul style="list-style-type: none"> • Dr. Robert Dickson • (Dr. Dana Kissner: back-up) • TB Nurses: <ul style="list-style-type: none"> • TB Nurse Coordinator (full-time): <ul style="list-style-type: none"> • Mary McCloud • TB Nurse Staff (part-time): <ul style="list-style-type: none"> • Karen Manni • Kelicia C. Byrd

3

**WASHTENAW COUNTY HEALTH DEPARTMENT
TUBERCULOSIS (TB) CONTROL PROGRAM**

Mission

- Legal responsibility for preventing and controlling TB in the community by:
 - Identifying and treating persons who have suspect/active TB and ensuring they complete appropriate therapy.
 - Identifying and screening contacts of persons with TB to determine whether they have latent TB infection or active disease and providing appropriate treatment.
 - Screening high-risk populations to detect persons with latent TB infection and providing appropriate treatment to prevent progression to disease.




4

**WASHTENAW COUNTY HEALTH DEPARTMENT
TUBERCULOSIS (TB) CONTROL PROGRAM**

Mission

- Legal responsibility for preventing and controlling TB in the community by:
 - Identifying and treating persons who have suspect/active TB and ensuring they complete appropriate therapy.
 - Identifying and screening contacts of persons with TB to determine whether they have latent TB infection or active disease and providing appropriate treatment.
 - Screening high-risk populations to detect persons with latent TB infection and providing appropriate treatment to prevent progression to disease.




5

**IMPETUS FOR CREATING A LTBI PROTOCOL FOR
PRIMARY CARE PROVIDERS IN WASHTENAW COUNTY**



- Capacity
- Empowerment
- Partnership



6

TUBERCULOSIS CASE RATES

Tuberculosis Case Rates					
	2018	2017	2016	2015	2014
United States		2.8	2.9	3.0	2.9
Michigan	1.1	1.3	1.3	1.3	1.1
Washtenaw County	2.4	2.2	2.8	1.7	1.9
Wayne County	2.3	2.5	3.1	2.5	2.3
Oakland County	1.5	2.0	1.3	1.4	1.4
Macomb County	0.6	1.4	1.3	1.6	1.2

Note: case rates are expressed as # of cases per 100,000 population. Population data used for each year are the most recent U.S. Census Bureau estimates for each year as of 02/14/2018.


MDHHS: https://www.michigan.gov/documents/mdhhs/owdM_County_TBIRCL140519_CASES_021418_1.pdf
 CDC: <http://www.cdc.gov/tb/statistics/reports/>

7

SCOPE OF THE PROBLEM

LTBI Reactivation:

- Reactivation of LTBI is a significant source of TB disease.
- Exposure to *Mycobacterium tuberculosis*: 30% will develop LTBI
 - Untreated: 5-10% will progress to active TB disease.
 - >80% TB cases (in U.S.) due to reactivated LTBI.




8

CRITICAL STRATEGY FOR ELIMINATION OF TB IN U.S.


Screening and treatment of persons at high-risk:

- LTBI
- Developing TB disease once infected with M. tuberculosis


-U.S. Public Health Service
-CDC




9




10



11




12



13

RISK FACTORS FOR TB INFECTION OR PROGRESSION

- Individuals born in or who frequently travel to countries where TB is endemic
- People who live in or have lived in high risk congregate settings (e.g. correctional facilities or homeless shelters or illicit drug use in group setting).
- Individuals who are in close contact with a person who has active TB disease.
- Healthcare workers and others who work in hospitals, nursing homes and other types of healthcare facilities .
- Immunosuppressed individuals including:
 - HIV infection
 - Hx organ transplant
 - Treatment with immunosuppressive medications:
 - TNF-alpha antagonist
 - Steroids dose (≥10-15mg/ per day for more than one month)
 - Other



14

A HIGHER RATE OF DISEASE PROGRESSION FOR INDIVIDUALS WITH:

- HIV infection
- Immunosuppression
- Diabetes Mellitus
- History of cigarette smoking
- History of illicit drug use



15

DIAGNOSTIC TESTING TWO TESTING METHODS

- **The Tuberculin Skin Test (TST)**
 - Detects cell mediated immunity by delayed hypersensitivity reaction to purified protein derivative (PPD).
- **Interferon Gamma Release Assays (IGRA)**
 - Measures the immune response to TB proteins in whole blood.
 - There are 2 FDA approved and commercially available IGRAs :
 - QuantiFERON®-TB Gold In-Tube test (QFT-GIT)
 - T-SPOT®.TB test (T-Spot)
- **The IGRAs are often preferable to TST for adults with:**
 - Low chance of returning for reading the test
 - Past receipt of the BCG vaccine
- **IGRA testing does not cause the booster phenomenon that can occur with using TST**

Important: Neither methods distinguishes between LTBI and TB disease.

19

YOU SHOULD KNOW: CAUSES OF FALSE-NEGATIVE TST


TST : some individuals may not react to the TST despite TB infection:

- Recent TB infection (within 8-10 weeks of exposure)
- Old TB infection (many years)
- Very young age (less than 6 months old)
- Recent live-virus vaccination (e.g., Measles/Mumps/Rubella, Varicella, and Smallpox)
- Overwhelming TB disease
- Some viral illnesses (e.g., measles and chicken pox)
- Incorrect method of TST administration
- Incorrect interpretation of reaction
- Cutaneous anergy

20

TREATMENT OF LTBI: AN IMPORTANT PUBLIC HEALTH INTERVENTION

- **Important:** LTBI treatment should be initiated only after TB disease has been ruled out!
- There is a high risk of drug resistance and treatment failure if a patient with TB disease is treated with a single drug regimen.
- Patients with suspected TB disease are managed by the local health department (LHD)
- Multidrug treatment regimen until the diagnosis is either confirmed or ruled out
- Determine need for baseline liver function tests (LFTs)
 - LFTs **normal**: proceed with treatment regimen
 - LFTs **not normal**: call the LHD for guidance



21

TREATMENT OF LTBI:
THE CDC RECOMMENDS SEVERAL REGIMEN OPTIONS FOR LTBI TREATMENT

Note: Patients are more likely to complete shorter treatment regimens

- INH and Rifapentine (RPT) or 3HP: 3 months once weekly under Directly Observed Therapy (DOT) or self-administered therapy (SAT)
- Rifampin (RIF) for 4 months daily
- Isoniazid (INH) for 9 months daily (or twice weekly under DOT)
- INH for 6 months daily (or twice weekly under DOT)



22

TREATMENT OF LTBI:
THE CDC RECOMMENDS SEVERAL REGIMEN OPTIONS FOR LTBI TREATMENT

Note: Patients are more likely to complete shorter treatment regimens

Regimens commonly used by WCHD TB Clinic:

- INH and Rifapentine (RPT) or 3HP: 3 months once weekly under Directly Observed Therapy (DOT)
- Rifampin (RIF) for 4 months daily
- Isoniazid (INH) for 9 months daily



23

TREATMENT OF LTBI:
THE CDC RECOMMENDS SEVERAL REGIMEN OPTIONS FOR LTBI TREATMENT

Note: Patients are more likely to complete shorter treatment regimens

Regimens commonly used by WCHD TB Clinic:

- INH and Rifapentine (RPT) or 3HP: 3 months once weekly under Directly Observed Therapy (DOT)
- Rifampin (RIF) for 4 months daily
- Isoniazid (INH) for 9 months daily

24


WASHTENAW COUNTY HEALTH DEPARTMENT LTBI PROTOCOL FOR ADULT HIV-NEGATIVE ADULTS

MONITORING:

- Determine appropriate level of monitoring
- Periodically assess the patient's progress:
 - Ensurance of safe and effective treatment
 - Components:
 1. Clinical monitoring
 - a. signs of hepatitis
 - b. adherence to the medication regimen
 - c. symptoms of possible adverse drug reactions or interactions
 1. Laboratory testing
 2. Patient education



25



26

(UPDATED) RECOMMENDED DRUG REGIMENS FOR LTBI TREATMENT			
Regimen	Duration	Notes	Additional Notes
9HR (900 mg/1500 mg)	9 months	For patients with TB infection who are HIV-negative and have no other TB infection. Not recommended for patients with TB infection who are HIV-positive, pregnant, severely immunosuppressed, or have other TB infection.	Requires lab increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Supplemental with pyridoxine (500 mg daily) to prevent B6 deficiency. Monitor for drug hypersensitivity reactions, ranging from mild rashes with an itchy rash to more severe reactions including hepatotoxicity and peripheral neuropathy.
9HRZ (900 mg/1500 mg/400 mg)	9 months	For patients with TB infection who are HIV-negative and have no other TB infection. Not recommended for patients with TB infection who are HIV-positive, pregnant, severely immunosuppressed, or have other TB infection.	Requires lab increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Supplemental with pyridoxine (500 mg daily) to prevent B6 deficiency. Monitor for drug hypersensitivity reactions, ranging from mild rashes with an itchy rash to more severe reactions including hepatotoxicity and peripheral neuropathy.
9HRZE (900 mg/1500 mg/400 mg/250 mg)	9 months	For patients with TB infection who are HIV-negative and have no other TB infection. Not recommended for patients with TB infection who are HIV-positive, pregnant, severely immunosuppressed, or have other TB infection.	Requires lab increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Supplemental with pyridoxine (500 mg daily) to prevent B6 deficiency. Monitor for drug hypersensitivity reactions, ranging from mild rashes with an itchy rash to more severe reactions including hepatotoxicity and peripheral neuropathy.
9HRZE (900 mg/1500 mg/400 mg/250 mg)	9 months	For patients with TB infection who are HIV-negative and have no other TB infection. Not recommended for patients with TB infection who are HIV-positive, pregnant, severely immunosuppressed, or have other TB infection.	Requires lab increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Supplemental with pyridoxine (500 mg daily) to prevent B6 deficiency. Monitor for drug hypersensitivity reactions, ranging from mild rashes with an itchy rash to more severe reactions including hepatotoxicity and peripheral neuropathy.

27

QUESTIONS?



31